BeiGene Plummets 10.59% as Surge in Liquidity Propels Volume to 346th in U.S. Rankings Amid Mixed Pipeline Updates

On September 10, 2025, , . The stock saw a surge in liquidity, . This sharp drop followed mixed signals from its pipeline developments and regulatory timelines.

Analysts noted that recent updates on BeiGene’s clinical-stage programs, including delays in Phase III trial data for its BTK inhibitor, contributed to investor caution. Additionally, uncertainty around potential label expansions for its PD-1 therapy in first-line gastric cancer applications created downward pressure. The company’s broader oncology portfolio remains under scrutiny, with market participants assessing whether near-term data readouts can offset long-term growth expectations.

Portfolio performance metrics from a back-test strategy—ranking U.S. stocks by daily trading volume and holding the top 500 names for one day—showed mixed results. , 2021–September 10, 2025), . , . These figures highlight the strategy’s sensitivity to short-term liquidity dynamics and market momentum shifts.